SG11202100781VA - Treatment of mucopolysaccharidosis iva - Google Patents

Treatment of mucopolysaccharidosis iva

Info

Publication number
SG11202100781VA
SG11202100781VA SG11202100781VA SG11202100781VA SG11202100781VA SG 11202100781V A SG11202100781V A SG 11202100781VA SG 11202100781V A SG11202100781V A SG 11202100781VA SG 11202100781V A SG11202100781V A SG 11202100781VA SG 11202100781V A SG11202100781V A SG 11202100781VA
Authority
SG
Singapore
Prior art keywords
treatment
mucopolysaccharidosis iva
mucopolysaccharidosis
iva
Prior art date
Application number
SG11202100781VA
Inventor
Shunji Tomatsu
Kazuki Sawamoto
Subha Karumuthil Melethil
Olivier Danos
Original Assignee
Regenxbio Inc
The Nemours Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc, The Nemours Found filed Critical Regenxbio Inc
Publication of SG11202100781VA publication Critical patent/SG11202100781VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11202100781VA 2018-07-27 2019-07-26 Treatment of mucopolysaccharidosis iva SG11202100781VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862711238P 2018-07-27 2018-07-27
US201862756880P 2018-11-07 2018-11-07
US201962799834P 2019-02-01 2019-02-01
PCT/US2019/043631 WO2020023857A1 (en) 2018-07-27 2019-07-26 Treatment of mucopolysaccharidosis iva

Publications (1)

Publication Number Publication Date
SG11202100781VA true SG11202100781VA (en) 2021-02-25

Family

ID=69180546

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100781VA SG11202100781VA (en) 2018-07-27 2019-07-26 Treatment of mucopolysaccharidosis iva

Country Status (12)

Country Link
US (1) US20210292789A1 (en)
EP (1) EP3829619A4 (en)
JP (1) JP2021531044A (en)
KR (1) KR20210040984A (en)
AU (1) AU2019312301A1 (en)
BR (1) BR112021001498A2 (en)
CA (1) CA3107800A1 (en)
CO (1) CO2021002505A2 (en)
IL (1) IL280343A (en)
SG (1) SG11202100781VA (en)
TW (1) TW202039857A (en)
WO (1) WO2020023857A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021021661A1 (en) * 2019-07-26 2021-02-04 Regenxbio Inc. Engineered nucleic acid regulatory element and methods of uses thereof
US20230064077A1 (en) * 2020-01-29 2023-03-02 Regenxbio Inc. Treatment of mucopolysaccharidosis iva
WO2023077092A1 (en) * 2021-10-28 2023-05-04 Regenxbio Inc. Engineered nucleic acid regulatory elements and methods and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207139A1 (en) * 2004-06-10 2007-09-06 Saint Louis University, A Non-Profit Organization Enhancing the effect of therapeutic proteins on the central nervous system
US7863238B2 (en) * 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US7972593B2 (en) * 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
JP5728389B2 (en) * 2009-01-30 2015-06-03 ユニキュアー アイピー ビー．ブイ． Alanine-glyoxylate aminotransferase therapeutic
US20140271550A1 (en) * 2013-03-14 2014-09-18 The Trustees Of The University Of Pennsylvania Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
US20160243260A1 (en) * 2013-10-24 2016-08-25 Uniqure Ip B.V. Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
JP6877408B2 (en) * 2015-08-31 2021-05-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア AAV-EPO for pet treatment
KR20210027266A (en) * 2018-05-30 2021-03-10 에스테베 파마슈티칼스 에스에이 Adeno-associated virus vector for the treatment of mucopolysaccharide accumulation syndrome IV type A

Also Published As

Publication number Publication date
TW202039857A (en) 2020-11-01
WO2020023857A1 (en) 2020-01-30
BR112021001498A2 (en) 2021-04-27
AU2019312301A1 (en) 2021-02-18
IL280343A (en) 2021-03-25
JP2021531044A (en) 2021-11-18
CO2021002505A2 (en) 2021-03-08
EP3829619A1 (en) 2021-06-09
EP3829619A4 (en) 2022-05-18
KR20210040984A (en) 2021-04-14
CA3107800A1 (en) 2020-01-30
US20210292789A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
GB201804514D0 (en) Treatment of pyroptosis
IL274865A (en) Methods of treatment with asparaginase
IL280343A (en) Treatment of mucopolysaccharidosis iva
ZA201907401B (en) Treatment of adipocytes
IL264451B1 (en) Combination of abt-199 and imetelstat for treatment of aml
IL279497A (en) Treatment of proteinuria
GB201804515D0 (en) Treatment of necroptosis
IL270362B (en) Treatment of glaucoma
GB201805100D0 (en) Treatment of sarcopenic diseases
GB201614415D0 (en) Enzymes for the treatment of human enterometabolic dysfunction
GB201907305D0 (en) Treatment of conditions
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
RS61481B1 (en) Treatment of migraine with acetyl-leucine
IL290983A (en) Methods of treatment
GB201917253D0 (en) Treatment of conditions
HUE064198T2 (en) Treatment of pneumonia
GB201918853D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment
GB201900942D0 (en) Methods of treatment
GB201815000D0 (en) Treatment of hypothroidism and related conditions
EP3727359C0 (en) Treatment of fibrosis with inositol
SG11202007642RA (en) Treatment of disorders with tasimelteon
IL274552A (en) Treatment of side effects of botulinum therapies
GB201816914D0 (en) Treatment of inflammation